Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2026)

Xeris Biopharma Holdings has reported Change in Receivables for 7 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 11.33% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (up 11.77% YoY), and the FY2025 full-year result was $10.6 million, up 773.15% from the prior year.
• Change in Receivables for Q1 2026 stood at $5.2 million, up from -$2.7 million in the prior quarter.
• The five-year high for Change in Receivables was $15.7 million in Q3 2023, with the low at -$6.8 million in Q4 2023.
• Historically, Change in Receivables has averaged $2.3 million across 5 years, with a median of $1.8 million in 2022.
• The largest YoY upside for Change in Receivables was 891.5% in 2024 against a maximum downside of 6043.33% in 2024.
• Xeris Biopharma Holdings' Change in Receivables stood at $3.3 million in 2022, then sank by 304.38% to -$6.8 million in 2023, then jumped by 89.32% to -$723000.0 in 2024, then sank by 273.58% to -$2.7 million in 2025, then surged by 294.19% to $5.2 million in 2026.
• The last three Change in Receivables figures came in at $5.2 million (Q1 2026), -$2.7 million (Q4 2025), and $703000.0 (Q3 2025), per Business Quant data.